Investors have once again turned to Chinese pharmaceutical company Jiangsu Hengrui to create a new biotech startup, this time ...

What is "fake" CPR, and why do doctors sometimes do it? STAT's Alex Hogan explains in this week's episode of STATus Report.

FDA's digital advisors could nudge the agency to clarify how its rules apply to medical applications of generative AI, ...

CPR can be brutal and ineffective for people clearly at the end of life, but families often insist on it anyway. How should ...

The aggravating prior authorization process includes one step that merits scrutiny and potentially regulatory action: the ...

Beware of financialization when it is code for “money making money on health,” with no plan for developing the staff, stuff, ...

Novo Nordisk's new CEO said he was confident in the company's pipeline of obesity drugs, but that buying Metsera would allow ...

A recent deep dive into the unraveling of Moderna by reporter Jason Mast is one of the most popular STAT stories of the year.

Exclusive: Arena Bioworks, the buzzy research institute that launched with $500 million to support a decade of scientific R&D ...

A deal with Lilly and Novo would be significant for the administration’s push for lower drug prices for Americans.

The new strategy shares themes with health secretary Robert F. Kennedy Jr.’s Make America Health Again agenda. He has called ...

We’re also continuing to track the fallout from all the recent FDA controversies.